Schwegman Lundberg & Woessner will be offering a webinar entitled "Interplay Between FDA Law and Patent Law: Avoiding Indigestion After Belcher v. Hospira" on September 27, 2021 from 12:00 pm to 1:30 pm (CT).  Suneel Arora, Timothy Christman, Lea Westman, and John Swart of Schwegman Lundberg & Woessner will discuss the Federal Circuit's decision in Belcher Pharmaceuticals, LLC v. Hospira, Inc., affirming a finding of unenforceability of a patent for inequitable conduct, inferring intent based in part on inconsistent representations that were made by the patentee to the U.S. Food & Drug Administration versus the U.S. Patent & Trademark Office.  The panel will also discuss other cases involving FDA/USPTO interplay, involving a range of considerations including patentability, duty of candor, infringement exemption under § 271(e)(1), and patent term extension for regulatory approval delay.

While there is no cost to participate in the program, those interested in attending the webinar can register here.